• AZD3463: Precision ALK/IGF1R Inhibitor for Neuroblastoma Wor

  2026-08-05

  AZD3463, a dual ALK/IGF1R inhibitor, streamlines neuroblastoma and ALK-driven cancer research with robust pathway inhibition and compatibility in combination therapy. Its high potency and ability to overcome resistance position it as a keystone for advanced translational studies.

• Mubritinib (TAK 165): Redefining Oxidative Phosphorylation T

  2026-08-05

  Explore how Mubritinib (TAK 165) advances research into chemotherapy-resistant AML and PEL by inhibiting mitochondrial complex I and disrupting OXPHOS. This article offers a uniquely integrative analysis, bridging mechanistic insights with practical assay design and cross-domain implications.

• SAR405 and the Future of Vps34 Inhibition in Translational R

  2026-08-04

  This thought-leadership article explores the evolving landscape of autophagy research, focusing on the mechanistic and translational implications of Vps34 inhibition using SAR405. Drawing from recent paradigm-shifting discoveries in AMPK-ULK1-Vps34 signaling, we provide in-depth protocol guidance, strategic context, and actionable recommendations for translational researchers seeking to leverage SAR405 for disease modeling and therapeutic innovation. The discussion is grounded in primary evidence and thoughtfully bridges mechanistic insight with practical assay design, highlighting how SAR405 from APExBIO empowers the next generation of autophagy and vesicle trafficking studies.

• Cholecystokinin Octapeptide Ammonium: Protocols, Use-Cases &

  2026-08-04

  Cholecystokinin octapeptide ammonium (CCK-8 ammonium) is a versatile neuropeptide tool for investigating behavior, apoptosis, and immune modulation across in vitro and in vivo systems. This article unlocks actionable protocols and troubleshooting insights, bridging foundational studies in zebrafish and mammalian models to help researchers harness APExBIO’s CCK-8 ammonium for robust, reproducible neurobehavioral and immunological assays.

• Mitoxantrone HCl: Optimized DNA Topoisomerase II Inhibitor W

  2026-08-03

  Mitoxantrone HCl unlocks advanced workflows for DNA damage, apoptosis, and nuclear receptor modulation across cancer and stem cell research. Recent studies reveal an unexpected mechanism—targeting ERα at an allosteric site—offering hope for overcoming therapy resistance and expanding experimental horizons.

• Aclacinomycin A Illuminates DNA Damage, Apoptosis, and rDNA

  2026-08-03

  Explore how Aclacinomycin A, a dual topoisomerase and proteasome inhibitor, enables advanced research into DNA damage, apoptosis, and persistent rDNA lesions. This article uniquely bridges molecular insight with assay selection, highlighting APExBIO’s rigorously validated product.

• Doxorubicin HCl: Mechanistic Precision and Translational Opp

  2026-08-02

  Explore how Doxorubicin hydrochloride (Adriamycin HCl) is redefining translational oncology research by blending mechanistic nuance with strategic workflow guidance. This article examines the molecular underpinnings of doxorubicin's action, innovative assay design, and the translational implications of emerging discoveries such as RNA-driven nuclear architecture. Strategic protocol parameters, competitive insights, and a forward-looking outlook equip researchers to advance precision oncology and model anthracycline cardiotoxicity with confidence.

• Peroxynitrite, Calcium Flux, and Necroptosis in Cardiac I/R

  2026-08-01

  Liu et al. (2025) reveal how hyperhomocysteinemia worsens cardiac microvascular ischemia-reperfusion injury through peroxynitrite-driven ER stress and pathological ER-mitochondria calcium transfer, culminating in necroptotic endothelial cell death. Their mechanistic study identifies the IP3R-mitochondrial axis as a tractable target for acute cardiovascular protection.

• Luminescent ATP Cell Viability Assay I: Elevating Ferroptosi

  2026-07-31

  Discover how the Luminescent ATP Cell Viability Assay Kit I revolutionizes cell viability measurement in ferroptosis studies using advanced luciferase luminescence detection. This article uniquely dissects mechanistic insights from recent ferroptosis research to guide assay selection and experimental design.

• Erlotinib (NSC 718781): Applied EGFR Inhibition in Cancer As

  2026-07-31

  Erlotinib (NSC 718781) empowers researchers to dissect EGFR-driven oncogenic signaling with precision, making it an essential tool for translational cancer biology. Discover optimized protocols and troubleshooting strategies for maximizing assay sensitivity and overcoming resistance mechanisms, including SCUBE3-mediated pathways.

• Mitoxantrone HCl: DNA Topoisomerase II Inhibitor for Researc

  2026-07-30

  Mitoxantrone HCl is a potent DNA topoisomerase II inhibitor widely used for inducing DNA damage and apoptosis in cancer and immunology research. Recent studies confirm its dual mechanism—classical DNA cleavage and allosteric modulation of nuclear receptors—making it essential for leukemia, multiple sclerosis, and advanced breast cancer models.

• Homer1a Suppresses Caspase-6 to Reduce Inflammatory Pain in

  2026-07-30

  This preclinical study demonstrates that Homer1a attenuates inflammatory pain in the spinal dorsal horn by inhibiting caspase-6 and TNF-α signaling. The findings identify the Homer1a/caspase-6 axis as a promising target for pain modulation and provide mechanistic insight into inflammatory nociception.

• One-step TUNEL Cy3 Apoptosis Detection Kit: Workflow, Use, a

  2026-07-29

  The One-step TUNEL Cy3 Apoptosis Detection Kit streamlines apoptosis detection with high sensitivity and robust workflow adaptability—ideal for both tissue sections and cultured cells. This article connects mechanistic insights from recent hepatic injury research to practical, reproducible assay choices for rigorous apoptosis research.

• Prochlorperazine: Dopamine D2 Antagonist in Melanoma Researc

  2026-07-29

  Prochlorperazine, a potent dopamine D2 receptor antagonist, is advancing experimental oncology and antiviral workflows with its multifaceted pharmacology. This article navigates practical use-cases, protocol optimizations, and troubleshooting in melanoma and antiemetic research, while translating lessons from clinical safety studies into robust in vitro assay design.

• DOT1L Inhibition Enhances Lenalidomide Response in Myeloma

  2026-07-28

  This study demonstrates that DOT1L inhibition reprograms innate immunity to potentiate the efficacy of immunomodulatory drugs, notably lenalidomide, in multiple myeloma. By elucidating the epigenetic and signaling mechanisms involved, the findings highlight new combinatorial strategies for overcoming resistance in myeloma research.

13909 records 1/928 page Next 12345 下5页 Last page